European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

PD-Podcast-DBS

The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.

The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.

Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.

“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”

For comprehensive information about Parkinson’s diagnosis please visit the EPDA website.

Go Back

Share this story

Comments


Related articles


Resources & Tools

Perspectives on relationships, intimacy and Parkinson’s disease

Four women share insights in a Davis Phinney Foundation webinar

READ MORE

Europe

Heinz Becker MEP: “Europe must take action for people with Parkinson’s”

My PD Journey will remove hurdles to optimal Parkinson's treatment

READ MORE
Robert Cochrane Boys of Summer

Interviews

Meet the filmmaker documenting his father’s Parkinson’s journey

Robert Cochrane tells us about his documentary series on Parkinson’s

READ MORE